Weight LossResearch

Retatrutide Therapy: Complete Guide

Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. In the Phase 2 TRIUMPH trial, participants on the highest dose lost an average of 24.2% of body weight over 48 weeks, with some Phase 3 cohorts reporting losses above 28%. Expected to file an NDA with the FDA in Q4 2026, retatrutide is widely anticipated to become the next major advance beyond tirzepatide for obesity and metabolic disease.

Typical cost: $400 - $900/month

What is Retatrutide?

What Is Retatrutide?

Retatrutide (development code LY3437943) is Eli Lilly's investigational triple-agonist peptide for obesity and type 2 diabetes. It is the first therapy in development to activate all three incretin-family receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Each receptor contributes a distinct metabolic lever — GLP-1 suppresses appetite, GIP enhances insulin signaling and fat metabolism, and glucagon increases energy expenditure. Combined, these pathways have produced the largest weight-loss results ever reported in a Phase 2 obesity trial.

Why Retatrutide Matters

Tirzepatide (Mounjaro/Zepbound) established the dual GIP/GLP-1 mechanism in 2022 with ~22.5% average weight loss in SURMOUNT-1. Retatrutide raises that ceiling further by adding glucagon receptor activation, which increases resting energy expenditure and enhances lipolysis. Phase 2 participants at the 12 mg dose lost an average of 24.2% of body weight over 48 weeks, and top Phase 3 readouts (including the TRIUMPH-4 cohort) have reported average losses approaching 28.7% — a figure that would have been considered impossible in weight-loss pharmacotherapy just five years ago.

Regulatory Timeline

Eli Lilly is conducting the TRIUMPH Phase 3 program across obesity, type 2 diabetes, obstructive sleep apnea, MASH (metabolic-associated steatohepatitis), and heart failure with preserved ejection fraction. An NDA filing is widely expected in Q4 2026, with potential FDA approval in 2027. Retatrutide is not yet commercially available, and legitimate access is currently limited to active clinical trials. Research-chemical vendors selling "retatrutide" are not providing FDA-regulated product, and patient safety cannot be assured through those channels.

How Retatrutide Works

Triple-Receptor Agonism

Retatrutide is a 39-amino-acid peptide engineered to activate three distinct receptors with calibrated potency. The balance between the three activities is a critical design feature — activation must be strong enough to drive therapeutic effects but balanced enough to avoid hyperglycemia from the glucagon arm.

GLP-1 Receptor Activation

As with semaglutide and tirzepatide, GLP-1 receptor activation in the hypothalamus reduces appetite and increases satiety. In the pancreas, it drives glucose-dependent insulin secretion and suppresses glucagon in the post-meal state. GLP-1 activity also slows gastric emptying, extending satiety after meals.

GIP Receptor Activation

GIP activation amplifies insulin release, improves beta-cell function, and — counterintuitively — enhances adipose tissue insulin sensitivity, which appears to reduce inflammation in fat depots. GIP activity is thought to contribute to the better GI tolerability of tirzepatide relative to semaglutide, and this pattern appears to extend to retatrutide.

Glucagon Receptor Activation

This is the novel arm. Glucagon is typically thought of as the counter-regulatory hormone that raises blood sugar, but its receptor activity also increases resting energy expenditure, enhances hepatic fat oxidation, and promotes lipolysis in adipose tissue. By pairing glucagon activity with strong GLP-1 and GIP signaling, retatrutide achieves weight loss through both reduced intake (appetite suppression) and increased output (energy expenditure) — a mechanism not available with single or dual agonists.

Pharmacokinetics

Retatrutide has a half-life supporting once-weekly subcutaneous dosing, similar to tirzepatide and semaglutide. A fatty acid side chain extends circulation by binding albumin.

Benefits & Uses

Clinical Benefits Reported in Trials

Weight loss: 17.5% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) mean body weight reduction over 48 weeks in Phase 2. Phase 3 cohorts reporting up to 28.7% at higher doses and longer follow-up.
Waist circumference: Reductions of 15–20 cm in high-dose arms, reflecting substantial visceral adipose loss.
Liver fat: Dramatic reductions in hepatic steatosis — Phase 2 MASH data showed ≥85% relative liver fat reduction in high-dose participants.
Glycemic control: HbA1c reductions of 1.6–2.0 percentage points in type 2 diabetes participants.
Blood pressure: Systolic BP reductions of 7–11 mmHg across dose ranges.
Triglycerides and lipids: Improvements in triglycerides, LDL, and HDL comparable to or exceeding tirzepatide.
Apnea-hypopnea index: Trials underway in obstructive sleep apnea; preliminary data favorable.

Mechanism-Driven Advantages

The glucagon component drives energy expenditure, meaning weight loss is not purely from reduced caloric intake. This may translate to better preservation of metabolic rate during and after weight loss — a potential advantage over caloric restriction and single-receptor agonists where metabolic adaptation can blunt long-term results.

Clinical Evidence & Research

Phase 2 Obesity Trial

Jastreboff et al., New England Journal of Medicine, 2023 — 338 participants with obesity randomized to retatrutide at 1, 4, 8, or 12 mg weekly vs placebo for 48 weeks. Mean body weight change: −24.2% at 12 mg, −22.1% at 8 mg, −17.5% at 4 mg, vs −2.1% placebo. More than 80% of participants in the 8 mg and 12 mg arms lost at least 15% of body weight. This is the strongest weight-loss result ever reported in a randomized obesity trial at the time of publication.

Phase 2 Type 2 Diabetes Trial

Rosenstock et al., The Lancet, 2023 — HbA1c reductions of 1.6–2.0% with weight loss of 8.9–16.9% across retatrutide doses over 36 weeks. Comparable or superior to dulaglutide and placebo arms.

Phase 2 MASH (Liver Disease)

Sanyal et al., 2024 — Reported relative reductions in liver fat of 82.4% at the 8 mg dose and 85.6% at 12 mg over 48 weeks in participants with hepatic steatosis, alongside substantial weight loss.

TRIUMPH Phase 3 Program

An umbrella of eight Phase 3 trials spanning obesity (TRIUMPH-1, -2, -3), type 2 diabetes (TRIUMPH-4), obstructive sleep apnea, MASH, knee osteoarthritis, and heart failure with preserved ejection fraction. Readouts through 2026 are expected to underpin Lilly's NDA submission.

Side Effects & Safety

Common Side Effects

Nausea — most common, particularly during dose escalation. Typically improves after 2–4 weeks at a given dose.
Vomiting — more common at high doses; slower titration reduces incidence.
Diarrhea — dose-dependent.
Constipation — frequent, especially at higher doses.
Decreased appetite — expected mechanism.
Injection-site reactions — mild redness or irritation.

Class-Level Concerns

Retatrutide carries the full incretin-family safety profile:

Pancreatitis risk (rare but requires monitoring).
Gallbladder disease, particularly with rapid weight loss.
Heart rate increase of 3–8 beats per minute reported in trials.
Thyroid C-cell tumor risk (boxed concern with GLP-1 class; animal-only signal).

Glucagon-Specific Considerations

The glucagon arm can raise blood glucose in susceptible patients. In clinical trials, dose titration is designed to balance glucagon activity against GLP-1/GIP activity. Patients with poorly controlled diabetes, severe hepatic impairment, or cardiovascular instability require careful evaluation and are typically excluded from current protocols.

Long-Term Safety

Follow-up beyond 48–72 weeks remains limited. The Phase 3 program is designed to generate multi-year safety data, particularly around cardiovascular outcomes and any metabolic rebound after discontinuation.

Dosing & Administration

Clinical Trial Dosing

Retatrutide is administered by weekly subcutaneous injection. Trial protocols use a careful titration approach because the therapeutic doses significantly exceed those used for semaglutide or tirzepatide:

Weeks 1–4: 2 mg weekly
Weeks 5–8: 4 mg weekly
Weeks 9–12: 6 mg weekly
Weeks 13–16: 8 mg weekly
Weeks 17+: 8 mg or 12 mg maintenance, depending on tolerability and weight-loss goals

Administration

Subcutaneous injection into the abdomen, thigh, or upper arm, with site rotation to minimize local irritation. The exact commercial dosing format (pre-filled pen vs multi-dose cartridge) will be set at FDA approval.

Current Access

Retatrutide is not yet FDA-approved and is not available by prescription. Legitimate access is limited to participation in active clinical trials. Consult clinicaltrials.gov for current enrollment opportunities and speak with a qualified provider about whether retatrutide trial enrollment may be appropriate for your situation. Research-chemical vendors selling "retatrutide" online are not providing an FDA-regulated product, and safety, potency, and purity cannot be guaranteed.

Find Retatrutide Providers Near You

Search our directory for qualified providers offering Retatrutide therapy. Filter by location, telehealth, and more.

Browse Providers

Retatrutide FAQ

Eli Lilly is expected to file an NDA in Q4 2026 based on TRIUMPH Phase 3 results. FDA decision typically takes 10–12 months under standard review, so commercial approval is likely in 2027. Retatrutide is not legitimately available by prescription today.

In Phase 2 trials, participants on 12 mg weekly lost an average of 24.2% of body weight over 48 weeks. Phase 3 cohorts at higher doses and longer follow-up have reported mean losses approaching 28.7%. More than 80% of high-dose participants lost at least 15% of body weight.

In cross-trial comparison, retatrutide produces larger mean weight loss than tirzepatide (24.2% vs ~22.5% over similar timeframes). However, retatrutide is not yet approved, and head-to-head randomized data are limited. Tirzepatide is the current best-in-class approved therapy; retatrutide is expected to raise the ceiling once approved.

The primary side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. Modest heart-rate increases (3–8 bpm) have been observed. The glucagon component can affect blood sugar in susceptible patients. Long-term safety is still being established through Phase 3.

No. Retatrutide is not FDA-approved and therefore cannot be legally compounded for patient use in the United States. Online "research peptide" vendors selling retatrutide are not providing FDA-regulated product, and patient safety, dose accuracy, and purity cannot be assured through those channels.

Semaglutide activates GLP-1 alone. Tirzepatide activates GLP-1 + GIP. Retatrutide adds a third lever — glucagon receptor activation — which increases resting energy expenditure and enhances fat oxidation. This triple mechanism produces greater weight loss than either single- or dual-agonist approaches.

Retatrutide Deep-Dive Questions

In-depth answers to the most common questions about Retatrutide, grouped by topic.